PRLog - Feb. 28, 2013 - Stoke-on-Trent, UK - As part of its ongoing work on biocompatibility and bioactivity of Hydroxyapatite (HA), Ceram (http://www.ceram.com/)
Calcium phosphate growth after SBF immersion
Gaining and maintaining regulatory approval of medical devices and materials, such as Hydroxyapatite (HA) can be a fraught, lengthy and complex process. Submission of data to regulatory bodies, for example the FDA (Food and Drug Administration)
The other white paper looks at various synthesis methods of HA, including precipitation, sol-gel and self-propagating combustion and demonstrates the vast variability of HA synthesised by some of the most popular methodologies.
With its newly-patented technology, Ceram’s aim is to work with clients to develop HA with tailored bioactivity, both for bone replacement materials applications and for new drug delivery systems with tailored bio-application requirements.
The white papers are free to download from Ceram’s website at http://www.ceram.com/
Ceram is an independent, international materials technology company that focuses on innovation, sustainability and quality assurance of materials.
Headquartered in Staffordshire, UK, and with approved laboratories around the world, Ceram solves product and process challenges across a range of materials to help clients improve performance, comply with regulations and develop their sustainability performance in order to gain a competitive advantage and increase profitability.
Ceram operates in a wide variety of sectors around the world.
For further information, please contact:
Ceram Marketing Executive
Phone: +44 (0)1782 764436